[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
May 2017

Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014

Author Affiliations
  • 1Section of Academic Pediatrics, Department of Pediatrics, University of Chicago, Chicago, Illinois
  • 2Department of Public Health Sciences, University of Chicago, Chicago, Illinois
  • 3Section of Pediatric Hematology/Oncology, Department of Pediatrics, University of Chicago, Chicago, Illinois
JAMA Intern Med. 2017;177(5):736-739. doi:10.1001/jamainternmed.2017.0252

In 2007, Mylan obtained the right to EpiPen, the most widely used epinephrine auto-injector for serious allergic reactions.1,2 Since then, Mylan has increased the list price for EpiPen from $94 to $609.2 In part due to patient outcry over rising out-of-pocket spending, Mylan released a $300 generic EpiPen in December 2016.3

Whether generic EpiPen decreases out-of-pocket spending depends largely on insurers’ benefit design. To date, the generosity of EpiPen coverage has not been well characterized. We assessed EpiPen out-of-pocket spending between January 2007 and December 2014 among the commercially insured, a population that accounts for 70% of annual EpiPen prescriptions.1